Investigating the role of early antigens in coccidioidomycosis and their impact on immune response and vaccines
Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis
This study is looking at how certain proteins from the coccidioidomycosis fungus affect how sick people get and how their immune systems respond, with the goal of creating better vaccines and tests for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern Arizona University NIH-funded |
| Lab location | 1 site (Flagstaff, United States) |
| Project ID | NIH-10899652 on NIH RePORTER |
What this research studies
This research focuses on understanding how early expressed antigens in coccidioidomycosis affect the disease's virulence and the immune response in patients. By collaborating with multiple institutions, the project aims to develop effective vaccines and improve diagnostic methods. The research involves a combination of laboratory studies and clinical evaluations to assess how these antigens can be targeted for better treatment outcomes. Patients may be involved in trials that test new vaccine candidates or diagnostic tools.
Who could benefit from this research
Good fit: Ideal candidates for participation would include individuals at risk for coccidioidomycosis or those who have been diagnosed with the disease.
Not a fit: Patients who do not have coccidioidomycosis or are not at risk for the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccines and treatments for coccidioidomycosis, enhancing patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting antigens for vaccine development in other infectious diseases, suggesting potential success for this approach.
Where this research is happening
Flagstaff, United States
- Northern Arizona University — Flagstaff, United States (Active)
Researchers
- Principal investigator: Keim, Paul Stephen — Northern Arizona University
- Study coordinator: Keim, Paul Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.